Hybribio’s Chloroquine Phosphate Gel Cleared for Clinical Trial on High-Risk HPV Infections

Hybribio Limited (SHE: 300639), a Guangdong-based pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its chloroquine phosphate gel, a patented pharmaceutical preparation in China. The gel, designed for topical administration, is intended to reduce systemic exposure and is formulated for the treatment of genital and perianal condyloma, commonly known as warts, resulting from human papilloma virus (HPV) infection. Initially approved by the NMPA in March 2018 for clinical use in treating various skin warts and HPV-induced genital and perianal warts, the drug is now poised for evaluation in the context of high-risk HPV infections.- Flcube.com